drugset
drugset / Trial / NCT01986556

Lesinurad Tablet Relative Bioavailability

NCT01986556 ↗

Phase 1 Completed 36 enrolled Ardea Biosciences, Inc.
RandomizedParallel-groupOpen-labelBasic science

Summary

This study will assess the relative bioavailability of lesinurad tablets, manufactured at two different sites.

Timeline

Start
2013-11
Primary completion
2014-04
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Lesinurad Small molecule 400 mg —

Indications

No indication recorded.